Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States

BACKGROUND: Prior to 2018, intravenous bisphosphonates (IV BPs) were the only therapies recommended to prevent skeletal‐related events for patients diagnosed with multiple myeloma (MM). We examined patterns of IV BP initiation and interruption among patients with newly diagnosed MM (NDMM) in the Uni...

Descripción completa

Detalles Bibliográficos
Autores principales: McGrath, Leah J., Hernandez, Rohini K., Overman, Robert, Reams, Diane, Liede, Alexander, Brookhart, M. Alan, O’Donnell, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Cancer Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346250/
https://www.ncbi.nlm.nih.gov/pubmed/30537194
http://dx.doi.org/10.1002/cam4.1869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346250/
https://www.ncbi.nlm.nih.gov/pubmed/30537194
http://dx.doi.org/10.1002/cam4.1869

Ejemplares similares